EP3-解析 3.5 代新藥 HCB101 的商業護城河 Decoding the Business Moat of HCB101
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
EP3-解析 3.5 代新藥 HCB101 的商業護城河 Decoding the Business Moat of HCB101
-
Letto da:
-
Di:
A proposito di questo titolo
【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作
為什麼 CD47 標靶藥物被稱為生技界的「百慕達三角洲」？過去無數國際大藥廠折戟沉沙的領域，漢康生技竟能以 2.02 億美金成功授權，並開發出改寫產業標準的 3.5 代新藥 HCB101？
本集我們特別邀請到漢康生技研發長翟文武博士。他擁有英國劍橋大學與美國 UCSF 頂尖研究背景，並曾在輝瑞、羅氏擔任要職的他，將深度解析漢康如何利用 FBDB 平台與 AI 建模技術，解決 CD47 藥物最致命的「溶血毒性」痛點。
精彩內容：
解密 CD47 通路： 癌細胞如何利用「別吃我」訊號躲避免疫系統？
破解前車之鑑： 第一、二代藥物為何失敗？漢康 3.5 代藥物的差異化優勢在哪？
AI 與抗體工程： 如何從收錄 1.8億筆資料庫中篩選出兼具「強效」與「安全」的分子？
以終為始的 CMC 製程： 為什麼「產量 6 g/L」與「自主掌握製程」是商業成功的基石？
未來的藍圖： HCB101 在頭頸癌、淋巴瘤與胃癌的驚人臨床表現，以及自體免疫疾病的新布局。
這不只是關於一場抗癌革命的紀錄，更是生技平台化轉型的經典案例。無論你是投資人、專業醫療從業人員，還是關心醫療科技發展的聽眾，都不容錯過！
【About This Episode】
Why is the CD47 target often called the "Bermuda Triangle" of drug development? While global pharmaceutical giants have struggled in this field, how did HanchorBio secure a $202 million licensing deal and develop HCB101, a 3.5-generation drug that is rewriting industry standards?
In this episode, we are honored to host Dr. Wenwu Zhai, Chief Research Officer of HNK Biotech. With a prestigious background from the University of Cambridge and UCSF, and leadership experience at Pfizer and Roche, Dr. Zhai provides a deep dive into how HNK utilizes its FBDB platform and AI modeling to solve the fatal "hemolytic toxicity" flaw that plagued previous generations of CD47 drugs.
【Key Takeaways】
Decoding CD47: How cancer cells use the "Don't Eat Me" signal to evade the immune system.
Learning from the Past: Why 1st and 2nd gen drugs failed, and the differentiated advantages of HNK’s 3.5-gen approach.
AI & Antibody Engineering: The process of screening 1.8 X 10^8 molecules to find the perfect balance of "potency" and "safety."
"Beginning with the End in Mind" (CMC): Why 6 g/L yield and in-house process control are the cornerstones of commercial success.
The Future Roadmap: HCB101’s remarkable clinical performance in head and neck cancer, stomach cancer and lymphoma, and its strategic expansion into autoimmune diseases.
This is more than a record of a cancer revolution; it is a masterclass in the "platformization" of biotech. Whether you are an investor, a medical professional, or a tech enthusiast, this is an episode you cannot miss!
漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9
本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。